20 February 2018
By Dr Wendy Winnall - PCFA Research Team
In 2014, a landmark publication in a top medical journal reported a biomarker test that could identify men with metastatic castration resistant prostate cancer who would not gain any benefit from taking Enzalutamide or Abiraterone. But unfortunately recent publications have now shown that this may not the case. Both these studies were performed by world-leading scientists and we have no reason to doubt their results. So how did we go from one of the most promising tests for a biomarker to one that doesn’t seem to work well enough, in less than 4 years?
To read the full article just log into the PCFA Online Community.
If you're not already a member, it is free and easy to join.
